Antanas Strazdas
Antanas Strazdas has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Almorad
Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Heart Rhythm Research Brussels, Postgraduate Program in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
1 shared publication - Alvise Del Monte
Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Heart Rhythm Research Brussels, Postgraduate Program in Cardiac Electrophysiology and Pacing Vrije Universiteit Brussel, European Reference Networks Guard‐Heart Brussels Belgium
1 shared publication - Anaïs Gauthey
University Hospital (UZ) Brussels , Brussels , Belgium
1 shared publication - Andrea Sarkozy
Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, European Reference Networks Guard-Heart , Brussels
1 shared publication - Antonio Bisignani
Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Heart Rhythm Research Brussels, Postgraduate Program in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium; Center of Excellence in Cardiovascular Sciences, Ospedale Isola Tiberina-Gemelli Isola, Rome, Italy
1 shared publication - Antonio Sorgente
Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Heart Rhythm Research Brussels, Postgraduate Program in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium
1 shared publication
Latest Publications
- 16 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Adding Non‐Occlusive Cryoballoon Ablation in Case of Ostial‐Level Pulmonary Vein Isolation or Carina Sparing Does Not Improve 1‐Year Outcome After Cryoballoon Ablation (the NOCA‐AF Study)
Introduction: Fixed‐diameter cryoballoon ablation (CBA) can yield suboptimal ostial‐level pulmonary vein isolation (PVI) and spare arrhythmogenic sites like the carina. The addition of non‐occlusive cryoballoon ablation (NOCA) could overcome this limitation of CBA. We aimed to assess the need and effectiveness of NOCA and its impact on clinical outcomes.Methods and Results: One hundred AF patients (66 ± 10 years, 40 females) were prospectively randomized to CBA (Control group, n = 50) or CBA + NOCA if needed (Study group, n = 50). Ostial‐level PVI and carina sparing was assessed by electroanatomic left atrial (LA) voltage mapping after CBA. Endpoint was documented AF/AFL/AT ( > 30 s) at 12 months, with Holters at 6 and 12 months. After CBA, ostial PVI level was seen in 110 out of 392 veins (28%), with predominance of the left superior PV and carina sparing in 11 (11%) left PVs and 16 (16%) right PVs. Overall, voltage mapping displayed a potential NOCA need in 68 (68%) patients. Spatially, for both PV sides, preferential ostial‐level PVI segments were situated at the posterior wall. NOCA was added in 38 (76%) study patients, confirmed effective in all by voltage remapping. At 1 year, AF/AFL/AT recurrence occurred in 12 (24%) Study and 6 (12%) control patients (p = 0.121).Conclusions: Ostial‐level PVI and carina sparing occurs in a substantial amount of patients treated by CBA. Although NOCA proved effective in extending the lesion size to antral‐level PVI or carina ablation, adding NOCA did not improve 1‐year clinical outcome.
- 16 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
Adding Non‐Occlusive Cryoballoon Ablation in Case of Ostial‐Level Pulmonary Vein Isolation or Carina Sparing Does Not Improve 1‐Year Outcome After Cryoballoon Ablation (the NOCA‐AF Study)
Introduction: Fixed‐diameter cryoballoon ablation (CBA) can yield suboptimal ostial‐level pulmonary vein isolation (PVI) and spare arrhythmogenic sites like the carina. The addition of non‐occlusive cryoballoon ablation (NOCA) could overcome this limitation of CBA. We aimed to assess the need and effectiveness of NOCA and its impact on clinical outcomes.Methods and Results: One hundred AF patients (66 ± 10 years, 40 females) were prospectively randomized to CBA (Control group, n = 50) or CBA + NOCA if needed (Study group, n = 50). Ostial‐level PVI and carina sparing was assessed by electroanatomic left atrial (LA) voltage mapping after CBA. Endpoint was documented AF/AFL/AT ( > 30 s) at 12 months, with Holters at 6 and 12 months. After CBA, ostial PVI level was seen in 110 out of 392 veins (28%), with predominance of the left superior PV and carina sparing in 11 (11%) left PVs and 16 (16%) right PVs. Overall, voltage mapping displayed a potential NOCA need in 68 (68%) patients. Spatially, for both PV sides, preferential ostial‐level PVI segments were situated at the posterior wall. NOCA was added in 38 (76%) study patients, confirmed effective in all by voltage remapping. At 1 year, AF/AFL/AT recurrence occurred in 12 (24%) Study and 6 (12%) control patients (p = 0.121).Conclusions: Ostial‐level PVI and carina sparing occurs in a substantial amount of patients treated by CBA. Although NOCA proved effective in extending the lesion size to antral‐level PVI or carina ablation, adding NOCA did not improve 1‐year clinical outcome.
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (4) , e012374
Genetic Testing in Brugada Syndrome: A 30-Year Experience
BACKGROUND: A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with American College of Medical Genetics and Genomics variant classification and to assess prognosis of SCN5A and non-SCN5A variants. METHODS: All patients with BrS, were prospectively enrolled in the Universitair Ziekenhuis Brussel registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following American College of Medical Genetics and Genomics guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A + . Patients with a reported variant in a non-SCN5A gene or with no reported variants were defined as patients with SCN5A − . All variants were classified as missense or predicted loss of function. RESULTS: A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A + and 396 patients (79.2%) were SCN5A − . A non-SCN5A gene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant in SCN5A + or non-SCN5A genes. There was no difference in VA-free survival between patients without any variant and missense variant carriers in SCN5A + or non-SCN5A genes. At Cox analysis, SCN5A + or non-SCN5A predicted loss of function variant was an independent predictor of VA. CONCLUSIONS: In a large BrS cohort, the yield for SCN5A + is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA.
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 17 (4) , e012374
Genetic Testing in Brugada Syndrome: A 30-Year Experience
BACKGROUND: A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with American College of Medical Genetics and Genomics variant classification and to assess prognosis of SCN5A and non-SCN5A variants. METHODS: All patients with BrS, were prospectively enrolled in the Universitair Ziekenhuis Brussel registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following American College of Medical Genetics and Genomics guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A + . Patients with a reported variant in a non-SCN5A gene or with no reported variants were defined as patients with SCN5A − . All variants were classified as missense or predicted loss of function. RESULTS: A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A + and 396 patients (79.2%) were SCN5A − . A non-SCN5A gene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant in SCN5A + or non-SCN5A genes. There was no difference in VA-free survival between patients without any variant and missense variant carriers in SCN5A + or non-SCN5A genes. At Cox analysis, SCN5A + or non-SCN5A predicted loss of function variant was an independent predictor of VA. CONCLUSIONS: In a large BrS cohort, the yield for SCN5A + is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA.
- Open Access
- 12 December 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 292
Heart rate variability after radiofrequency ablation of epicardial ganglionated plexuses on the ovine left atrium
Ganglionated plexuses (GP) are terminal parts of cardiac autonomous nervous system (ANS). Radiofrequency ablation (RFA) for atrial fibrillation (AF) possibly affects GP. Changes in heart rate variability (HRV) after RFA can reflect ANS modulation. Epicardial RFA of GP on the left atrium (LA) was performed under the general anesthesia in 15 mature Romanov sheep. HRV was used to assess the alterations in autonomic regulation of the heart. A 24 − hour ECG monitoring was performed before the ablation, 2 days after it and at each of the 12 following months. Ablation sites were evaluated histologically. There was an instant change in HRV parameters after the ablation. A standard deviation of all intervals between normal QRS (SDNN), a square root of the mean of the squared differences between successive normal QRS intervals (RMSSD) along with HRV triangular index (TI), low frequency (LF) power and high frequency (HF) power decreased, while LF/HF ratio increased. Both the SDNN, LF power and the HF power changes persisted throughout the 12 − month follow − up. Significant decrease in RMSSD persisted only for 3 months, HRV TI for 6 months and increase in LF/HF ratio for 7 months of the follow − up. Afterwards these three parameters were not different from the preprocedural values. Epicardial RFA of GP’s on the ovine left atrium has lasting effect on the main HRV parameters (SDNN, HF power and LF power). The normalization of RMSSD, HRV TI and LF/HF suggests that HRV after epicardial RFA of GPs on the left atrium might restore over time.
- 12 December 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 292
Open AccessHeart rate variability after radiofrequency ablation of epicardial ganglionated plexuses on the ovine left atrium
Ganglionated plexuses (GP) are terminal parts of cardiac autonomous nervous system (ANS). Radiofrequency ablation (RFA) for atrial fibrillation (AF) possibly affects GP. Changes in heart rate variability (HRV) after RFA can reflect ANS modulation. Epicardial RFA of GP on the left atrium (LA) was performed under the general anesthesia in 15 mature Romanov sheep. HRV was used to assess the alterations in autonomic regulation of the heart. A 24 − hour ECG monitoring was performed before the ablation, 2 days after it and at each of the 12 following months. Ablation sites were evaluated histologically. There was an instant change in HRV parameters after the ablation. A standard deviation of all intervals between normal QRS (SDNN), a square root of the mean of the squared differences between successive normal QRS intervals (RMSSD) along with HRV triangular index (TI), low frequency (LF) power and high frequency (HF) power decreased, while LF/HF ratio increased. Both the SDNN, LF power and the HF power changes persisted throughout the 12 − month follow − up. Significant decrease in RMSSD persisted only for 3 months, HRV TI for 6 months and increase in LF/HF ratio for 7 months of the follow − up. Afterwards these three parameters were not different from the preprocedural values. Epicardial RFA of GP’s on the ovine left atrium has lasting effect on the main HRV parameters (SDNN, HF power and LF power). The normalization of RMSSD, HRV TI and LF/HF suggests that HRV after epicardial RFA of GPs on the left atrium might restore over time.